Trade Mark Journal No.2018/017 27 April 2018

WO0000001393810 (5,42)

Office of origin: United States

Date of International Registration:20 December 2017
Date of designation in the UK: 20 December 2017
Image for mark WO0000001393810 AGENTUS

International priority date claimed: 23 June 2017 (United States) (87502704)
Class 5
Cells for medical or clinical use; pharmaceutical and biopharmaceutical agents for the treatment of cancer, infectious disease, autoimmune disorders, transplant rejections, and inflammatory disease; pharmaceutical and biopharmaceutical preparations and substances for the treatment of cancer, infectious disease, autoimmune disorders, transplant rejections, and inflammatory disease.
Class 42
Pharmaceutical, medical, scientific, and biopharmaceutical research and development.

Agenus Inc.

Representative: Christina M. Licursi Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston MA 02210-2206, UNITED STATES OF AMERICA